A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)

Trial Profile

A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Gemcabene (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms COBALT-1
  • Sponsors Gemphire Therapeutics
  • Most Recent Events

    • 25 Sep 2017 The complete data from this study will also be submitted for publication in a peer reviewed journal, according to a Gemphire Therapeutics media release
    • 25 Sep 2017 According to a Gemphire Therapeutics media release, the company is planning to share data from this study with the FDA and EMA in end of Phase 2 meetings.
    • 25 Sep 2017 According to a Gemphire Therapeutics media release, results from this study presented at the 2017 FH Global Summit.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top